Atara Biotherapeutics, Inc. is a cutting-edge biotech company focused on developing innovative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases. Boasting an impressive pipeline of immunotherapy products, Atara Biotherapeutics is making a significant contribution to the fight against some of the most challenging illnesses of our time. At the forefront of the company's product lineup is Tab-cel (tabelecleucel), a T-cell immunotherapy program that is currently progressing through Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma. Additionally, the company's CAR T immunotherapy products, ATA2271 and ATA3271, are being developed to treat mesothelin, while ATA3219 aims to tackle B-cell malignancies. Atara Biotherapeutics is also making waves in the multiple sclerosis space with ATA188, which is currently undergoing Phase 2 clinical trials. Notably, Atara Biotherapeutics has secured partnerships with several prestigious institutions, including Memorial Sloan Kettering Cancer Center, QIMR Berghofer Medical Research Institute, and H. Lee Moffitt Cancer Center. These collaborations have enabled Atara Biotherapeutics to advance its research and development efforts and bring innovative therapies to market more quickly. Founded in 2012 and headquartered in Thousand Oaks, California, Atara Biotherapeutics is well-positioned to continue its significant contributions to the field of biotechnology in the years to come.
Atara Biotherapeutics's ticker is ATRA
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 201-500 employees working at Atara Biotherapeutics
It is atarabio.com
Atara Biotherapeutics is in the Healthcare sector
Atara Biotherapeutics is in the Biotechnology industry
The following five companies are Atara Biotherapeutics's industry peers: